Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J.
Chiappori A, et al. Among authors: liepa am.
J Thorac Oncol. 2010 Mar;5(3):369-75. doi: 10.1097/JTO.0b013e3181cee24f.
J Thorac Oncol. 2010.
PMID: 20090562
Free article.
Clinical Trial.